Publications
1248 results found
Badiani A, Berridge KC, Heilig M, et al., 2018, Addiction research and theory: a commentary on the Surgeon General's Report on alcohol, drugs, and health, ADDICTION BIOLOGY, Vol: 23, Pages: 3-5, ISSN: 1355-6215
- Author Web Link
- Cite
- Citations: 2
Carhart-Harris RL, Bolstridge M, Day CMJ, et al., 2018, Psilocybin with psychological support for treatment-resistant depression: six-month follow-up, PSYCHOPHARMACOLOGY, Vol: 235, Pages: 399-408, ISSN: 0033-3158
- Author Web Link
- Open Access Link
- Cite
- Citations: 6
Carrillo F, Sigman M, Fernandez Slezak D, et al., 2018, Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression, JOURNAL OF AFFECTIVE DISORDERS, Vol: 230, Pages: 84-86, ISSN: 0165-0327
Curran HV, Nutt D, de Wit H, 2018, Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation, PSYCHOPHARMACOLOGY, Vol: 235, Pages: 373-375, ISSN: 0033-3158
Dukart J, Holiga S, Chatham C, et al., 2018, Cerebral blood flow predicts differential neurotransmitter activity, SCIENTIFIC REPORTS, Vol: 8, ISSN: 2045-2322
Freeman TP, Pope RA, Wall MB, et al., 2018, Cannabis Dampens the Effects of Music in Brain Regions Sensitive to Reward and Emotion, INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, Vol: 21, Pages: 21-32, ISSN: 1461-1457
- Author Web Link
- Open Access Link
- Cite
- Citations: 1
Gabay AS, Carhart-Harris RL, Mazibuko N, et al., 2018, Psilocybin and MDMA reduce costly punishment in the Ultimatum Game, SCIENTIFIC REPORTS, Vol: 8, ISSN: 2045-2322
Heal DJ, Henningfield J, Frenguelli BG, et al., 2018, Psychedelics - Re-opening the doors of perception., Neuropharmacology
Kaelen M, Giribaldi B, Raine J, et al., 2018, The hidden therapist: evidence for a central role of music in psychedelic therapy, PSYCHOPHARMACOLOGY, Vol: 235, Pages: 505-519, ISSN: 0033-3158
- Author Web Link
- Open Access Link
- Cite
- Citations: 2
Kaelen M, Giribaldi B, Raine J, et al., 2018, The hidden therapist: evidence for a central role of music in psychedelic therapy (vol 235, pg 505, 2018), PSYCHOPHARMACOLOGY, Vol: 235, Pages: 1623-1623, ISSN: 0033-3158
Morris LS, Baek K, Tait R, et al., 2018, Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals, ADDICTION BIOLOGY, Vol: 23, Pages: 425-436, ISSN: 1355-6215
Rogeberg O, Bergsvik D, Phillips LD, et al., 2018, A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation, INTERNATIONAL JOURNAL OF DRUG POLICY, Vol: 56, Pages: 144-152, ISSN: 0955-3959
- Author Web Link
- Open Access Link
- Cite
- Citations: 2
Rogeberg O, Blomkvist AW, Nutt D, 2018, CANNABIS AND OPIOID OVERDOSES: TIME TO MOVE ON AND EXAMINE POTENTIAL MECHANISMS, ADDICTION, Vol: 113, Pages: 1551-1552, ISSN: 0965-2140
Roseman L, Nutt DJ, Carhart-Harris RL, 2018, Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression, FRONTIERS IN PHARMACOLOGY, Vol: 8, ISSN: 1663-9812
- Author Web Link
- Open Access Link
- Cite
- Citations: 9
Stroud JB, Freeman TP, Leech R, et al., 2018, Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression, PSYCHOPHARMACOLOGY, Vol: 235, Pages: 459-466, ISSN: 0033-3158
Turton S, Myers JF, Mick I, et al., 2018, Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals., Mol Psychiatry
Addiction has been proposed as a 'reward deficient' state, which is compensated for with substance use. There is growing evidence of dysregulation in the opioid system, which plays a key role in reward, underpinning addiction. Low levels of endogenous opioids are implicated in vulnerability for developing alcohol dependence (AD) and high mu-opioid receptor (MOR) availability in early abstinence is associated with greater craving. This high MOR availability is proposed to be the target of opioid antagonist medication to prevent relapse. However, changes in endogenous opioid tone in AD are poorly characterised and are important to understand as opioid antagonists do not help everyone with AD. We used [11C]carfentanil, a selective MOR agonist positron emission tomography (PET) radioligand, to investigate endogenous opioid tone in AD for the first time. We recruited 13 abstinent male AD and 15 control participants who underwent two [11C]carfentanil PET scans, one before and one 3 h following a 0.5 mg/kg oral dose of dexamphetamine to measure baseline MOR availability and endogenous opioid release. We found significantly blunted dexamphetamine-induced opioid release in 5 out of 10 regions-of-interest including insula, frontal lobe and putamen in AD compared with controls, but no significantly higher MOR availability AD participants compared with HC in any region. This study is comparable to our previous results of blunted dexamphetamine-induced opioid release in gambling disorder, suggesting that this dysregulation in opioid tone is common to both behavioural and substance addictions.
Tyacke RJ, Myers JFM, Venkataraman A, et al., 2018, Evaluation of 11C-BU99008, a positron emission tomography ligand for the Imidazoline2 binding site in human brain., J Nucl Med
The imidazoline2 binding site (I2BS), are thought to be expressed in glia, and implicated in the regulation of glial fibrillary acidic protein. A PET ligand for this target would be important for the investigation of neurodegenerative and neuroinflammatory diseases. 11C-BU99008 has previously been identified as a putative PET radioligand. Here we present the first in vivo characterisation of this PET radioligand in humans and assess its test-retest reproducibility. Methods 14 healthy male volunteers underwent dynamic PET imaging with 11C-BU99008 and arterial sampling. Six subjects were used to assess test-retest and eight were used in the pharmacological evaluation, undergoing a second, or third heterologous competition scan with the mixed I2BS/α2-adrenoceptor drug, idazoxan (n=8; 20, 40, 60 and 80mg) and the mixed irreversible MAOA/B inhibitor, isocarboxazid (n=4; 50mg), respectively. Regional time-activity data were generated from arterial plasma input functions corrected for metabolites using the most appropriate model to derive the outcome measure VT (regional total distribution volume). All image processing and kinetic analysis was performed in MIAKAT™ (www.miakat.org). Results Brain uptake of 11C-BU99008 was good with reversible kinetics and a heterogeneous distribution consistent with known I2BS expression. Model selection criteria indicated that the 2-tissue-compartment was preferred. VT estimates were high in the striatum (113±20 mL·cm-3), medium in cortex frontal lobe (55±9 mL·cm-3) and low in the cerebellum (47±7 mL·cm-3). Test-retest reliability was found to be reasonable. The uptake was dose-dependently reduced by pre-treatment with idazoxan throughout the brain, with an average block across all regions of ~60% (VT = ~30 mL·cm-3) at the highest dose (80 mg). The ED50 for idazoxan was calculated as 33.1 mg. Uptake was not blocked by pre-treatment with the MAO inhibitor, isocarboxazid. Conclusio
van den Brink W, Addolorato G, Aubin H-J, et al., 2018, Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level, ADDICTION BIOLOGY, Vol: 23, Pages: 969-986, ISSN: 1355-6215
Andersson M, Horder J, Mendez M, et al., 2017, A multicenter positron emission tomography study of GABA receptor availability in adults with autism, 30th Congress of the European-College-of-Neuropsychopharmacology (ECNP), Publisher: ELSEVIER SCIENCE BV, Pages: S716-S717, ISSN: 0924-977X
Bandelow B, Baldwin D, Abelli M, et al., 2017, Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition, WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, Vol: 18, Pages: 162-214, ISSN: 1562-2975
- Author Web Link
- Cite
- Citations: 13
Carhart-Harris RL, Nutt DJ, 2017, Serotonin and brain function: a tale of two receptors, JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 31, Pages: 1091-1120, ISSN: 0269-8811
- Author Web Link
- Open Access Link
- Cite
- Citations: 13
Carhart-Harris RL, Roseman L, Bolstridge M, et al., 2017, Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms, SCIENTIFIC REPORTS, Vol: 7, ISSN: 2045-2322
- Author Web Link
- Open Access Link
- Cite
- Citations: 13
Casajuana Kogel C, Mercedes Balcells-Olivero M, Lopez-Pelayo H, et al., 2017, The Standard Joint Unit, DRUG AND ALCOHOL DEPENDENCE, Vol: 176, Pages: 109-116, ISSN: 0376-8716
- Author Web Link
- Cite
- Citations: 2
Davies B, Brown LA, Cais O, et al., 2017, A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability, HUMAN MOLECULAR GENETICS, Vol: 26, Pages: 3869-3882, ISSN: 0964-6906
Erritzoe D, Colasanti A, Searle G, et al., 2017, Serotonin release measured in the human brain: A PET study with [C-11]Cimbi-36 and d-amphetamine challenge, 28th International Symposium on Cerebral Blood Flow, Metabolism and Function / 13th International Conference on Quantification of Brain Function with PET, Publisher: SAGE PUBLICATIONS INC, Pages: 73-73, ISSN: 0271-678X
- Author Web Link
- Cite
- Citations: 1
Erritzoe D, Nutt DJ, Carhart-Harris R, 2017, Concerns regarding conclusions made about LSD-treatments, HISTORY OF PSYCHIATRY, Vol: 28, Pages: 257-258, ISSN: 0957-154X
- Author Web Link
- Cite
- Citations: 2
Freeman TP, Pope R, Wall M, et al., 2017, Cannabis increases wanting but not liking of music and dampens its rewarding effects on the brain, European-College-of-Neuropsychopharmacology (ECNP) Workshop for Junior Scientists in Europe, Publisher: ELSEVIER SCIENCE BV, Pages: S92-S93, ISSN: 0924-977X
Law FD, Diaper AM, Melichar JK, et al., 2017, Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals, JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 31, Pages: 1046-1055, ISSN: 0269-8811
- Author Web Link
- Open Access Link
- Cite
- Citations: 2
Limbrick-Oldfield EH, Mick I, Cocks RE, et al., 2017, Neural substrates of cue reactivity and craving in gambling disorder, TRANSLATIONAL PSYCHIATRY, Vol: 7, ISSN: 2158-3188
- Author Web Link
- Open Access Link
- Cite
- Citations: 8
Maron E, Nutt D, 2017, Biological markers of generalized anxiety disorder, DIALOGUES IN CLINICAL NEUROSCIENCE, Vol: 19, Pages: 147-157, ISSN: 1294-8322
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.